These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12119860)

  • 1. Economic endpoints in clinical trials.
    Hlatky MA
    Epidemiol Rev; 2002; 24(1):80-4. PubMed ID: 12119860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using inverse-weighting in cost-effectiveness analysis with censored data.
    Willan AR; Lin DY; Cook RJ; Chen EB
    Stat Methods Med Res; 2002 Dec; 11(6):539-51. PubMed ID: 12516988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
    Wang H; Zhao H
    Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods.
    Graves N; Walker D; Raine R; Hutchings A; Roberts JA
    Health Econ; 2002 Dec; 11(8):735-9. PubMed ID: 12457373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.
    O'Hagan A; Stevens JW
    Stat Methods Med Res; 2002 Dec; 11(6):469-90. PubMed ID: 12516985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis and interpretation of cost data in randomised controlled trials: review of published studies.
    Barber JA; Thompson SG
    BMJ; 1998 Oct; 317(7167):1195-200. PubMed ID: 9794854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychopharmacology: the need for effectiveness trials to inform evidence-based psychiatric practice.
    Lagomasino IT; Dwight-Johnson M; Simpson GM
    Psychiatr Serv; 2005 Jun; 56(6):649-51. PubMed ID: 15939939
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic endpoints in clinical trials.
    Cook J; Drummond M; Heyse JF
    Stat Methods Med Res; 2004 Apr; 13(2):157-76. PubMed ID: 15068259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of medical records and patient questionnaires as sources for the estimation of costs within research studies and the implications for economic evaluation.
    Gillespie P; O'Shea E; Smith SM; Cupples ME; Murphy AW
    Fam Pract; 2016 Dec; 33(6):733-739. PubMed ID: 27587565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological design for economic evaluation in Public Access Defibrillation (PAD) trial.
    Nichol G; Wells GA; Kuntz K; Feeny D; Longstreth W; Mahoney B; Mann C; Lucas R; Henry M; Huszti E; Birnbaum A
    Am Heart J; 2005 Aug; 150(2):202-8. PubMed ID: 16086918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes assessment in nuclear cardiology.
    Shaw LJ; Miller DD; Berman DS; Hachamovitch R
    Q J Nucl Med; 2000 Jun; 44(2):138-52. PubMed ID: 10967624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation in long-term clinical trials.
    Hlatky MA; Boothroyd DB; Johnstone IM
    Stat Med; 2002 Oct; 21(19):2879-88. PubMed ID: 12325104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient use of endpoints in clinical trials: a clinical perspective.
    Terrin ML
    Stat Med; 1990; 9(1-2):155-60. PubMed ID: 2111931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting the cost right in cost-effectiveness analyses.
    Wolff N; Helminiak TW; Tebes JK
    Am J Psychiatry; 1997 Jun; 154(6):736-43. PubMed ID: 9167499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple tests of cost-effectiveness angles.
    Gutjahr G; Brannath W
    Stat Med; 2013 May; 32(10):1754-62. PubMed ID: 22826103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should cost data in pragmatic randomised trials be analysed?
    Thompson SG; Barber JA
    BMJ; 2000 Apr; 320(7243):1197-200. PubMed ID: 10784550
    [No Abstract]   [Full Text] [Related]  

  • 19. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.